Elizabeth E. Wicks, MD

🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and HIF-2, key regulators that help tumors adapt to hypoxia. ➡️ These compounds bind HIF proteins, block their activity and trigger their degradation, shutting down pathways that drive tumor growth, angiogenesis and immune evasion. ➡️ In preclinical models, dual HIF inhibition suppressed tumor growth across multiple cancer types and outperformed selective HIF-2 inhibitors. ➡️ When combined with immune checkpoint blockade in murine models, response rates exceeded 50% and helped overcome resistance to immunotherapy. 🌟 Targeting #hypoxia may help reprogram the tumor microenvironment and unlock stronger immune responses. 🔗 Read the study: rupress.org/jem/article/223/… @JohnsHopkins @HopkinsMedicine @umsop @eewicks @onlyoscarli

Yongkang Yang, Gregg Semenza et al. show that, in response to intratumoral #hypoxia, #BreastCancer cells co-opt an antiviral mechanism to promote #cancer #StemCell specification and immune evasion, which are essential properties that enable #metastasis. hubs.la/Q03X_GWp0

Innovative pain control after aSAH: Intra-MMA lidocaine (± dexamethasone) during embolization cut pain scores up to 75% and slashed opioid use—with no complications. Targeted dural therapy shows promise. #NeuroIR #subarachnoidhemorrhage #PainManagement #MMAembo bit.ly/43qkDfr